Suppr超能文献

通过下一代测序分析中国未选择乳腺癌患者的BRCA1/2突变谱及发生率

Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.

作者信息

Li Guoli, Guo Xinwu, Tang Lili, Chen Ming, Luo Xipeng, Peng Limin, Xu Xunxun, Wang Shouman, Xiao Zhi, Yi Wenjun, Dai Lizhong, Wang Jun

机构信息

The State Key Laboratory of Medical Genetics & School of Life Sciences, Central South University, 172 Tongzipo Road, Changsha, Hunan, 410013, China.

Sanway Gene Technology Inc., Changsha, Hunan, 410205, China.

出版信息

J Cancer Res Clin Oncol. 2017 Oct;143(10):2011-2024. doi: 10.1007/s00432-017-2465-8. Epub 2017 Jun 29.

Abstract

PURPOSE

BRCA1 and BRCA2 (BRCA1/2) are two major high-penetrance breast cancer predisposition genes, mutations in which can lead to high risks and early onset of breast cancer. This study was performed to comprehensively investigate the spectrum and prevalence of BRCA1/2 mutations in unselected Chinese breast cancer patients and evaluate the associations of BRCA1/2 mutations with related clinicopathological characteristics of the tumors.

METHODS

By integrating microfluidic PCR-based target enrichment and next-generation sequencing, paired tumor and normal tissues from 313 unselected breast cancer patients were analyzed for both germline and somatic mutations of BRCA1/2 genes in Chinese Han population.

RESULTS

Total 5 BRCA1 and 8 BRCA2 deleterious germline mutations were detected in 5 (1.60%) and 12 (3.83%) of the 313 patients, respectively. The entire frequency of deleterious germline mutations of BRCA1/2 was 5.43%. Among them, c.1069A > T and c.3418_3419insTGACTACT in BRCA1, c.8474_8487delCATACCCTATACAG and c.6547delG in BRCA2 were novel. In addition, 32 germline variants of unknown significance in 31 (9.90%) of the 313 patients were identified. We also detected 13 somatic mutations in ten patients (3.19%), including 4 (1.28%) deleterious mutations (c.1575delT, c.2677C > T, c.7024C > T, and c.7672G > T in BRCA2) and 5 novel mutations (c.4728A > G and c.4820T > C in BRCA1; c.2527G > A, c.4069C > G and c.7672G > T in BRCA2). Notably, BRCA1 mutation carriers were significantly younger, and more likely to be ER negative and basal-like breast cancers.

CONCLUSIONS

Our study provided a reliable and effective platform for BRCA1/2 genetic testing, and suggested that there was a relatively high prevalence and special spectrum of BRCA1/2 mutations in unselected Chinese breast cancer patients.

摘要

目的

BRCA1和BRCA2(BRCA1/2)是两个主要的高外显率乳腺癌易感基因,其突变可导致乳腺癌的高风险和早发。本研究旨在全面调查未经选择的中国乳腺癌患者中BRCA1/2突变的谱型和发生率,并评估BRCA1/2突变与肿瘤相关临床病理特征的相关性。

方法

通过整合基于微流控PCR的靶向富集和二代测序技术,对313例未经选择的中国汉族乳腺癌患者的配对肿瘤组织和正常组织进行BRCA1/2基因的胚系和体细胞突变分析。

结果

在313例患者中,分别在5例(1.60%)和12例(3.83%)中检测到5个BRCA1和8个BRCA2有害胚系突变。BRCA1/2有害胚系突变的总频率为5.43%。其中,BRCA1中的c.1069A>T和c.3418_3419insTGACTACT,BRCA2中的c.8474_8487delCATACCCTATACAG和c.6547delG为新发现的突变。此外,在313例患者中的31例(9.90%)中鉴定出32个意义未明的胚系变异。我们还在10例患者(3.19%)中检测到13个体细胞突变,包括4个(1.28%)有害突变(BRCA2中的c.1575delT、c.2677C>T、c.7024C>T和c.7672G>T)和5个新突变(BRCA1中的c.4728A>G和c.4820T>C;BRCA2中的c.2527G>A、c.4069C>G和c.7672G>T)。值得注意的是,BRCA1突变携带者明显更年轻,且更可能为雌激素受体阴性和基底样乳腺癌。

结论

我们的研究为BRCA1/2基因检测提供了一个可靠有效的平台,并表明在未经选择的中国乳腺癌患者中,BRCA1/2突变的发生率相对较高且谱型特殊。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验